Acetaldehyde Acetic Acid Alpine Strawberry Anhydro
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acetaldehyde Acetic Acid Alpine Strawberry Anhydro
- Multi-Ingredient Compound (30 Components): Insufficient Data for Drug Repurposing Evaluation
Multi-Ingredient Compound (30 Components): Insufficient Data for Drug Repurposing Evaluation
One-Sentence Summary
This submission contains a 30-ingredient complex formulation — including botanical extracts (Echinacea purpurea, Nux vomica seed, Lycopodium clavatum), animal-derived materials (cow milk, pork liver, adrenal gland, horseshoe crab), conventional pharmaceuticals (cortisone acetate, estrone, caffeine), and various excipients — that cannot be resolved to a single drug entity in any regulatory database. The TxGNN model returned no predicted indications for this compound, and the formulation currently holds no market authorization in Taiwan. Without a recognizable drug identity, DrugBank mapping, or approved indication, this candidate cannot proceed through standard repurposing evaluation at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None identified — no regulatory approval record found |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions generated; model could not process multi-ingredient compound as a single entity) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The TxGNN knowledge graph model is designed to operate on single drug entities mapped via DrugBank ID. This submission presents 30 distinct chemical and biological ingredients simultaneously as a single query string. Several structural issues prevent evaluation:
-
No DrugBank ID was resolved. TxGNN requires a valid DrugBank node as the starting point for graph traversal. Without this anchor, the model cannot compute disease proximity scores.
-
Heterogeneous ingredient classes. The formulation mixes conventional pharmaceuticals (cortisone acetate, estrone), herbal extracts (Echinacea purpurea, Strychnos nux-vomica seed), animal tissues (pork liver, Sus scrofa adrenal gland, Limulus polyphemus), and industrial excipients (paraffin, silicon dioxide, sodium bicarbonate). This composition pattern is characteristic of isopathic or homeopathic compound preparations, which lie outside the TxGNN training corpus.
-
No mechanism of action data is available. Without MOA information, the mechanistic rationale section cannot be completed.
Safety Considerations
Please refer to the package insert for safety information.
Note: Cortisone acetate and estrone are pharmacologically active ingredients present in this formulation. If this preparation is intended for clinical or investigational use, steroid-related and estrogen-related contraindications and drug interactions should be evaluated against current prescribing references prior to any human exposure.
Conclusion and Next Steps
Decision: Hold
Rationale: This compound cannot be evaluated under the current TxGNN drug repurposing framework because it does not resolve to a single identifiable drug entity with a DrugBank node, has no approved indication, and has no predicted disease associations. The presence of pharmacologically active steroids (cortisone acetate, estrone) in an otherwise homeopathic-style formulation also raises safety characterisation questions that must be resolved before any repurposing signal can be interpreted.
To proceed, the following is needed:
- Drug identity clarification: Determine whether this is a registered homeopathic/isopathic product; if so, identify the product name, manufacturer, and any existing regulatory dossier
- Individual component analysis: If repurposing evaluation is desired, consider submitting each pharmacologically active ingredient (cortisone acetate, estrone, caffeine) separately as individual TxGNN queries
- DrugBank mapping: Resolve at least the conventional pharmaceutical components to DrugBank IDs to enable graph-based prediction
- TFDA package insert retrieval (Data Gap DG001): Download and parse the prescribing information PDF to obtain approved warnings and contraindications
- MOA documentation (Data Gap DG002): Query DrugBank API for mechanism of action for each active component
- Regulatory status clarification: Confirm whether this product is marketed under any national pharmacopoeia, homeopathic registry, or special licence in any jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.